{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:59:30Z","timestamp":1791302370312,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009389","name":"Promobilia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009389","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Brain Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004063","name":"Knut and Alice Wallenberg Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["New Biotechnology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.nbt.2026.07.002","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:09:23Z","timestamp":1784128163000},"page":"14-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Biparatopic affibody engineering enables high-affinity sortilin blockade and progranulin elevation"],"prefix":"10.1016","volume":"95","author":[{"given":"Moira","family":"Ek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"St\u00e5hl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9423-0541","authenticated-orcid":false,"given":"John","family":"L\u00f6fblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbt.2026.07.002_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2025.3307","article-title":"Incidence and prevalence of frontotemporal dementia: a systematic review and meta-analysis","author":"Urso","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nbt.2026.07.002_bib2","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2021.2161","article-title":"Global prevalence of young-onset dementia: a systematic review and meta-analysis","volume":"78","author":"Hendriks","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nbt.2026.07.002_bib3","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1177\/1533317513494442","article-title":"Clinical Subtypes of Frontotemporal Dementia","volume":"30","author":"Ghosh","year":"2015","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.1016\/j.nbt.2026.07.002_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/nyas.12638","article-title":"Frontotemporal dementia: A bridge between dementia and neuromuscular disease","volume":"1338","author":"Ng","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.nbt.2026.07.002_bib5","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1176\/appi.neuropsych.21060166","article-title":"Advances in Treatment of Frontotemporal Dementia","volume":"34","author":"Magrath Guimet","year":"2022","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.nbt.2026.07.002_bib6","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1212\/WNL.0b013e3181bf997a","article-title":"The heritability and genetics of frontotemporal lobar degeneration","volume":"73","author":"Rohrer","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.nbt.2026.07.002_bib7","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1007\/s00415-014-7474-9","article-title":"Heritability in frontotemporal dementia: more missing pieces","volume":"261","author":"Po","year":"2014","journal-title":"J Neurol"},{"key":"10.1016\/j.nbt.2026.07.002_bib8","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1212\/01.wnl.0000319702.37497.72","article-title":"Distinct genetic forms of frontotemporal dementia","volume":"71","author":"Seelaar","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.nbt.2026.07.002_bib9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1474-4422(19)30394-1","article-title":"Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study","volume":"19","author":"Moore","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nbt.2026.07.002_bib10","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/brain\/awm331","article-title":"Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: Comparison with patients with MAPT and no known mutations","volume":"131","author":"Pickering-Brown","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.nbt.2026.07.002_bib11","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/nature05017","article-title":"Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21","volume":"442","author":"Cruts","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.nbt.2026.07.002_bib12","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1093\/hmg\/ddl241","article-title":"Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration","volume":"15","author":"Gass","year":"2006","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nbt.2026.07.002_bib13","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nsb0996-747","article-title":"The hairpin stack fold, a novel protein architecture for a new family of protein growth factors","volume":"3","author":"Hrabal","year":"1996","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.nbt.2026.07.002_bib14","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1073\/pnas.89.5.1715","article-title":"Isolation and sequence of the granulin precursor cDNA from human bone marrow reveals tandem cysteine-rich granulin domains","volume":"89","author":"Bhandari","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.nbt.2026.07.002_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-017-0196-6","article-title":"The lysosomal protein cathepsin L is a progranulin protease","volume":"12","author":"Lee","year":"2017","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.nbt.2026.07.002_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035115","article-title":"Regulation of Progranulin Expression in Human Microglia and Proteolysis of Progranulin by Matrix Metalloproteinase-12 (MMP-12)","volume":"7","author":"Suh","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.nbt.2026.07.002_bib17","first-page":"867","volume":"111","author":"Zhu","year":"2002","journal-title":"Conversion proepithelin epithelins Roles SLPI elastase host defense wound repair. Cell"},{"key":"10.1016\/j.nbt.2026.07.002_bib18","first-page":"7","article-title":"A single\u2013cell type transcriptomics map of human tissues","author":"Karlsson","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.nbt.2026.07.002_bib19","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1093\/hmg\/ddx162","article-title":"Progranulin functions as a cathepsin D chaperone to stimulate axonal outgrowth in vivo","volume":"26","author":"Beel","year":"2017","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nbt.2026.07.002_bib20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1083\/jcb.200712039","article-title":"Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival","volume":"181","author":"Van Damme","year":"2008","journal-title":"J Cell Biol"},{"key":"10.1016\/j.nbt.2026.07.002_bib21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1189\/jlb.0812429","article-title":"Insights into the role of progranulin in immunity, infection, and inflammation","volume":"93","author":"Jian","year":"2013","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.nbt.2026.07.002_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-018-1861-8","article-title":"The lysosomal function of progranulin, a guardian against neurodegeneration","volume":"136","author":"Paushter","year":"2018","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.nbt.2026.07.002_bib23","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/nature05016","article-title":"Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17","volume":"442","author":"Baker","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.nbt.2026.07.002_bib24","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000447738","article-title":"Progranulin Levels in Plasma and Cerebrospinal Fluid in Granulin Mutation Carriers","volume":"6","author":"Meeter","year":"2016","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"10.1016\/j.nbt.2026.07.002_bib25","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/brain\/awn352","article-title":"Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members","volume":"132","author":"Finch","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.nbt.2026.07.002_bib26","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1212\/01.wnl.0000325058.10218.fc","article-title":"Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration","volume":"71","author":"Ghidoni","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.nbt.2026.07.002_bib27","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/s41591-024-02973-0","article-title":"Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1\/2 trial interim results","volume":"30","author":"Sevigny","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.nbt.2026.07.002_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101622","article-title":"Intrathalamic delivery of adeno-associated viral vector expressing progranulin as gene therapy for GRN-related frontotemporal dementia","volume":"33","author":"Lee","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.nbt.2026.07.002_bib29","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1016\/j.cell.2021.08.002","article-title":"Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic","volume":"184","author":"Logan","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.nbt.2026.07.002_bib30","first-page":"1","article-title":"Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia","author":"Kurnellas","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.nbt.2026.07.002_bib31","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.neuron.2010.09.034","article-title":"Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin","volume":"68","author":"Hu","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.nbt.2026.07.002_bib32","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.ajhg.2010.11.002","article-title":"Genome-wide screen identifies rs646776 near sortilin as a regulator of progranulin levels in human plasma","volume":"87","author":"Carrasquillo","year":"2010","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nbt.2026.07.002_bib33","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.neurobiolaging.2013.04.022","article-title":"The neurotrophic properties of progranulin depend on the granulin E domain but do not require sortilin binding","volume":"34","author":"De Muynck","year":"2013","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.nbt.2026.07.002_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1326-7-33","article-title":"Progranulin regulates neuronal outgrowth independent of Sortilin","volume":"7","author":"Gass","year":"2012","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.nbt.2026.07.002_bib35","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/hmg\/ddt534","article-title":"Targeted manipulation of the sortilin-progranulin axis rescues progranulin haploinsufficiency","volume":"23","author":"Lee","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nbt.2026.07.002_bib36","first-page":"14","article-title":"Anti-sortilin1 antibody up-regulates progranulin via sortilin1 down-regulation","author":"Miyakawa","year":"2020","journal-title":"Front Neurosci"},{"key":"10.1016\/j.nbt.2026.07.002_bib37","first-page":"1","article-title":"Development of AL101 (GSK4527226), a progranulin-elevating monoclonal antibody, as a potential treatment for Alzheimer\u2019s disease","volume":"17","author":"Budda","year":"2025","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"10.1016\/j.nbt.2026.07.002_bib38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/protein\/1.2.107","article-title":"A synthetic IgG-binding domain based on staphylococcal protein A","volume":"1","author":"Nilsson","year":"1987","journal-title":"Protein Eng Des Sel"},{"key":"10.1016\/j.nbt.2026.07.002_bib39","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nbt0897-772","article-title":"Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain","volume":"15","author":"Nord","year":"1997","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.nbt.2026.07.002_bib40","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tibtech.2017.04.007","article-title":"Affibody molecules in biotechnological and medical applications","volume":"35","author":"St\u00e5hl","year":"2017","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.nbt.2026.07.002_bib41","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1074\/jbc.M110.164848","article-title":"Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain","volume":"286","author":"Andersen","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nbt.2026.07.002_bib42","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ard.2025.02.019","article-title":"Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"84","author":"Taylor","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nbt.2026.07.002_bib43","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/bjd\/ljad186","article-title":"Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment","volume":"189","author":"Gerdes","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.nbt.2026.07.002_bib44","first-page":"15","article-title":"An anti-sortilin affibody-peptide fusion inhibits sortilin-mediated progranulin degradation","author":"Ek","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.nbt.2026.07.002_bib45","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/protein\/gzn028","article-title":"Engineering of a femtomolar affinity binding protein to human serum albumin","volume":"21","author":"Jonsson","year":"2008","journal-title":"Protein Eng Des Sel"},{"key":"10.1016\/j.nbt.2026.07.002_bib46","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.bmcl.2013.11.046","article-title":"The identification of AF38469: An orally bioavailable inhibitor of the VPS10P family sorting receptor Sortilin","volume":"24","author":"Schr\u00f8der","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.nbt.2026.07.002_bib47","article-title":"C-terminus of progranulin interacts with the beta-propeller region of sortilin to regulate progranulin trafficking","volume":"6","author":"Zheng","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.nbt.2026.07.002_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-01485-5","article-title":"Low pH-induced conformational change and dimerization of sortilin triggers endocytosed ligand release","volume":"8","author":"Leloup","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.nbt.2026.07.002_bib49","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.str.2017.09.015","article-title":"Acidic environment induces dimerization and ligand binding site collapse in the Vps10p domain of sortilin","volume":"25","author":"Januliene","year":"2017","journal-title":"Structure"},{"key":"10.1016\/j.nbt.2026.07.002_bib50","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1002\/1873-3468.13181","article-title":"Crystal structure of the ligand-free form of the Vps10 ectodomain of dimerized Sortilin at acidic pH","volume":"592","author":"Yabe-Wada","year":"2018","journal-title":"FEBS Lett"},{"key":"10.1016\/j.nbt.2026.07.002_bib51","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1073\/pnas.93.12.5688","article-title":"Minimizing a binding domain from protein A","author":"Braisted","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.nbt.2026.07.002_bib52","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/cbic.200900062","article-title":"Engineered two-helix small proteins for molecular recognition","volume":"10","author":"Webster","year":"2009","journal-title":"ChemBioChem"},{"key":"10.1016\/j.nbt.2026.07.002_bib53","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3390\/ijms24010836","article-title":"Construction and validation of a new na\u00efve Sequestrin library for directed evolution of binders against aggregation-prone peptides","volume":"24","author":"Hjelm","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nbt.2026.07.002_bib54","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1073\/pnas.0711731105","article-title":"Stabilization of a \u03b2-hairpin in monomeric Alzheimer\u2019s amyloid-\u03b2 peptide inhibits amyloid formation","volume":"105","author":"Hoyer","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.nbt.2026.07.002_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep07518","article-title":"Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity","volume":"4","author":"Fleetwood","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.nbt.2026.07.002_bib56","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.nbt.2023.09.002","article-title":"Affibody-based hBCMA x CD16 dual engagers for NK cell-mediated killing of multiple myeloma cells","volume":"77","author":"Giang","year":"2023","journal-title":"N Biotechnol"},{"key":"10.1016\/j.nbt.2026.07.002_bib57","first-page":"16","article-title":"Biparatopic antibodies: therapeutic applications and prospects","author":"Niquille","year":"2024","journal-title":"MAbs"},{"key":"10.1016\/j.nbt.2026.07.002_bib58","unstructured":"Alector Inc. Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update 2025. https:\/\/investors.alector.com\/news-releases\/news-release-details\/alector-announces-topline-results-latozinemab-phase-3-trial\/ (accessed October 22, 2025)."},{"key":"10.1016\/j.nbt.2026.07.002_bib59","first-page":"4","article-title":"Regulation of lysosomal trafficking of progranulin by sortilin and prosaposin","author":"Du","year":"2022","journal-title":"Brain Commun"},{"key":"10.1016\/j.nbt.2026.07.002_bib60","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1083\/jcb.201502029","article-title":"Prosaposin facilitates sortilin-independent lysosomal trafficking of progranulin","volume":"210","author":"Zhou","year":"2015","journal-title":"J Cell Biol"},{"key":"10.1016\/j.nbt.2026.07.002_bib61","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/nm.3672","article-title":"Progranulin protects against amyloid \u03b2 deposition and toxicity in Alzheimer\u2019s disease mouse models","volume":"20","author":"Minami","year":"2014","journal-title":"Nat Med"},{"issue":"54","key":"10.1016\/j.nbt.2026.07.002_bib62","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","article-title":"New insights into the genetic etiology of Alzheimer\u2019s disease and related dementias","author":"Bellenguez","year":"2022","journal-title":"Nat Genet"},{"key":"10.1016\/j.nbt.2026.07.002_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.139394","article-title":"Identification of potential therapeutic targets for Alzheimer\u2019s disease from the proteomes of plasma and cerebrospinal fluid in a multicenter Mendelian randomization study","volume":"294","author":"Wang","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.nbt.2026.07.002_bib64","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1212\/01.wnl.0000289191.54852.75","article-title":"Progranulin genetic variability contributes to amyotrophic lateral sclerosis","volume":"71","author":"Sleegers","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.nbt.2026.07.002_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2020.134873","article-title":"Reduced plasma progranulin levels are associated with the severity of Parkinson\u2019s disease","volume":"725","author":"Yao","year":"2020","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.nbt.2026.07.002_bib66","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","article-title":"Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies","volume":"18","author":"Nalls","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nbt.2026.07.002_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097032","article-title":"Progranulin gene delivery protects dopaminergic neurons in a mouse model of Parkinson\u2019s disease","volume":"9","author":"Van Kampen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.nbt.2026.07.002_bib68","first-page":"5","article-title":"Sortilin gates neurotensin and BDNF signaling to control peripheral neuropathic pain","author":"Richner","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.nbt.2026.07.002_bib69","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1582-4934.2011.01350.x","article-title":"Progranulin contributes to endogenous mechanisms of pain defense after nerve injury in mice","volume":"16","author":"Lim","year":"2012","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.nbt.2026.07.002_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-018-1060-5","article-title":"Sortilin inhibition limits secretion-induced progranulin-dependent breast cancer progression and cancer stem cell expansion","volume":"20","author":"Rhost","year":"2018","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.nbt.2026.07.002_bib71","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.3390\/cancers15092514","article-title":"The membrane protein sortilin is a potential biomarker and target for glioblastoma","volume":"15","author":"Marsland","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.nbt.2026.07.002_bib72","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.3390\/ijms21082999","article-title":"An Affibody molecule is actively transported into the cerebrospinal fluid via binding to the transferrin receptor","volume":"21","author":"Meister","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nbt.2026.07.002_bib73","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3390\/ph16070956","article-title":"Affibody molecules intended for receptor-mediated transcytosis via the transferrin receptor","volume":"16","author":"Hjelm","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.nbt.2026.07.002_bib74","doi-asserted-by":"crossref","first-page":"15039","DOI":"10.1073\/pnas.1005025107","article-title":"Structural basis for high-affinity HER2 receptor binding by an engineered protein","volume":"107","author":"Eigenbrot","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.nbt.2026.07.002_bib75","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pro.3943","article-title":"UCSF ChimeraX: Structure visualization for researchers, educators, and developers","volume":"30","author":"Pettersen","year":"2021","journal-title":"Protein Sci"}],"container-title":["New Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871678426000944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871678426000944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:36:57Z","timestamp":1791301017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871678426000944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":75,"alternative-id":["S1871678426000944"],"URL":"https:\/\/doi.org\/10.1016\/j.nbt.2026.07.002","relation":{},"ISSN":["1871-6784"],"issn-type":[{"value":"1871-6784","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biparatopic affibody engineering enables high-affinity sortilin blockade and progranulin elevation","name":"articletitle","label":"Article Title"},{"value":"New Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbt.2026.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}